派格生物医药-B(02565)发布年度业绩研发开支5038.7万元已成功构建覆盖七款针对慢性疾病领域的在研药物管线矩阵

智通财经03-23

智通财经APP讯，派格生物医药-B(02565)发布截至2025年12月31日止年度业绩，该集团取得其他净收入18.9万元(人民币，下同);研发开支5038.7万元;每股基本亏损0.55元。截至本公告日期，我们在于美国及中国推进技术创新、产品管线及业务营运方面取得重大进展。截至本公告日期，派格生物已成功构建覆盖七款针对慢性疾病领域的在研药物管线矩阵。公司核心战略聚焦于代谢性疾病及其并发症的治疗，...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2621776330?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-03-23 16:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2621776330","market":"fut","top_or_hot":-1,"title":"派格生物医药-B(02565)发布年度业绩 研发开支5038.7万元 已成功构建覆盖七款针对慢性疾病领域的在研药物管线矩阵","media":"智通财经","content":"<div>\n<p>智通财经APP讯，派格生物医药-B(02565)发布截至2025年12月31日止年度业绩，该集团取得其他净收入18.9万元(人民币，下同);研发开支5038.7万元;每股基本亏损0.55元。截至本公告日期，我们在于美国及中国推进技术创新、产品管线及业务营运方面取得重大进展。截至本公告日期，派格生物已成功构建覆盖七款针对慢性疾病领域的在研药物管线矩阵。公司核心战略聚焦于代谢性疾病及其并发症的治疗，...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1417343.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>派格生物医药-B(02565)发布年度业绩 研发开支5038.7万元 已成功构建覆盖七款针对慢性疾病领域的在研药物管线矩阵</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n派格生物医药-B(02565)发布年度业绩 研发开支5038.7万元 已成功构建覆盖七款针对慢性疾病领域的在研药物管线矩阵\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-23 16:38 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1417343.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，派格生物医药-B(02565)发布截至2025年12月31日止年度业绩，该集团取得其他净收入18.9万元(人民币，下同);研发开支5038.7万元;每股基本亏损0.55元。截至本公告日期，我们在于美国及中国推进技术创新、产品管线及业务营运方面取得重大进展。截至本公告日期，派格生物已成功构建覆盖七款针对慢性疾病领域的在研药物管线矩阵。公司核心战略聚焦于代谢性疾病及其并发症的治疗，...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1417343.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"161726","symbol_name":"生物医药","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1417343.html","article_id":"2621776330","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2621776330","pubTimestamp":1774255101,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，派格生物医药-B 发布截至2025年12月31日止年度业绩，该集团取得其他净收入18.9万元;研发开支5038.7万元;每股基本亏损0.55元。截至本公告日期，我们在于美国及中国推进技术创新、产品管线及业务营运方面取得重大进展。截至本公告日期，派格生物已成功构建覆盖七款针对慢性疾病领域的在研药物管线矩阵。随着核心产品派达康于2025年11月成功获得上市批准，集团将全面推进其在中国市场的商业化落地工作。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"161726":"生物医药","399441":"生物医药","02565":"派格生物医药-B","BK4588":"碎股","BK4585":"ETF&股票定投概念","XBI":"SPDR S&P Biotech ETF","BK1161":"生物科技","BK4581":"高盛持仓"},"translate_title":"Paige Biomedical-B (02565) released its annual results R&D expenses of 50.387 million yuan and has successfully built a pipeline matrix covering seven drugs under development for chronic diseases","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"161726":1.5,"399441":1.5,"02565":1.5,"XBI":1.5},"content_text":"智通财经APP讯，派格生物医药-B(02565)发布截至2025年12月31日止年度业绩，该集团取得其他净收入18.9万元(人民币，下同);研发开支5038.7万元;每股基本亏损0.55元。截至本公告日期，我们在于美国及中国推进技术创新、产品管线及业务营运方面取得重大进展。截至本公告日期，派格生物已成功构建覆盖七款针对慢性疾病领域的在研药物管线矩阵。公司核心战略聚焦于代谢性疾病及其并发症的治疗，通过持续创新，内部评估显示多款候选药物兼具“同类首创”(FIC)与“同类最优”(BIC)的双重价值潜力，为未来市场竞争力奠定坚实基础。随着核心产品派达康®(PB-119)于2025年11月成功获得上市批准，集团将全面推进其在中国市场的商业化落地工作。未来，集团将围绕产品上市后的市场准入推进、商业化运营体系完善及患者可及性提升等方面持续开展相关工作，以支持产品上市后的市场渗透及临床使用场景拓展，并逐步推动产品价值的释放。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2621776330","isCrawlerRequest":true}

派格生物医药-B(02565)发布年度业绩 研发开支5038.7万元 已成功构建覆盖七款针对慢性疾病领域的在研药物管线矩阵

精彩评论

派格生物医药-B(02565)发布年度业绩研发开支5038.7万元已成功构建覆盖七款针对慢性疾病领域的在研药物管线矩阵